Tabrophage

Tabrecta (Capmatinib) Tablets for Metastatic Non-Small Cell Lung Cancer

Tabrecta is a medication specifically designed for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). It is indicated for patients whose tumors have a mutation that leads to MET exon 14 skipping, as detected by an FDA-approved test. This mutation results in a protein with a missing regulatory domain, which reduces its negative regulation and leads to increased downstream MET signaling.

How It Works:

Capmatinib, the active ingredient in Tabrecta, is a kinase inhibitor that targets the MET protein, including the mutant variant produced by exon 14 skipping. By inhibiting this protein, Tabrecta helps to reduce the growth and spread of cancer cells.

Dosage and Administration:

The recommended dosage of Tabrecta is 400 mg orally twice daily, with or without food. It is essential to select patients for treatment based on the presence of the MET exon 14 skipping mutation in their tumor specimens.

Important Safety Information:

• Interstitial Lung Disease (ILD)/Pneumonitis: Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. Permanently discontinue Tabrecta in patients with ILD/pneumonitis.
• Hepatotoxicity: Monitor liver function tests regularly. If liver damage occurs, reduce the dose or discontinue the medication.

Product Details:

Tabrecta is available in two strengths: 150 mg and 200 mg. The tablets are ovaloid, curved, and film-coated with beveled edges. The 150 mg tablets are pale orange-brown, while the 200 mg tablets are yellow.

Clinical Benefits:

Tabrecta has shown promising results in clinical trials, with an overall response rate and duration of response that support its use in treating metastatic NSCLC with MET exon 14 skipping mutations. However, continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.